Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftobiprole medocaril - Basilea Pharmaceutica

Drug Profile

Ceftobiprole medocaril - Basilea Pharmaceutica

Alternative Names: BAL-5788; BAL-9141; Ceftobiprole; Ceftobiprole medocaril sodium; JNJ-30982081; Mabelio; RO-65-5788; Zeftera; Zevtera

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Avir Pharma; Basilea Pharmaceutica; Department of Health & Human Services; Grupo Biotoscana; Hikma Pharmaceuticals; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development
  • Class Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Nosocomial pneumonia
  • Phase III Bacteraemia; Skin and soft tissue infections
  • No development reported Paediatric infections

Most Recent Events

  • 20 Aug 2019 Basilea announces intention to submit NDA to the US FDA for Bacteremia
  • 07 Aug 2019 Basilea announces intention to submit NDA to the US FDA for Skin and soft tissue infection in USA
  • 06 Aug 2019 Efficacy and adverse event data from a phase III TARGET trial in Skin and soft tissue infection released by Basilea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top